Pregledni rad
https://doi.org/10.26800/LV-145-supl1-9
Allergen immunotherapy in the treatment of asthma
Irena Ivković-Jureković
orcid.org/0000-0001-5024-7149
; Odjel za pulmologiju, alergologiju, imunologiju i reumatologiju, Klinika za dječje bolesti Zagreb, Fakultet za dentalnu medicinu i zdravstvo, Sveučilište Josipa Jurja Strossmayera u Osijeku, Medicinski fakultet Sveučilišta u Zagrebu
Sažetak
Allergen immunotherapy (AIT) is to date the sole etiologic treatment of allergic diseases with proven efficacy and safety in allergic rhinitis and asthma. In addition to reducing the symptoms and the need for medication, AIT can influence the course of the disease and induce allergen-specific immune tolerance. In treatment of allergic asthma AIT is delivered either subcutaneously or sublingually. Both modes of delivery have similar clinical efficacy and capacity to modify the underlying allergic disease, which persist years after AIT discontinuation. Due to its superior safety profile and lower risk of severe allergic adverse reactions, along with simple and painless
application, sublingual AIT is the treatment of choice in pediatric allergic respiratory diseases. Randomized clinical trials as well as real-life trials have shown that AIT can prevent new allergen sensitizations and reduce the risk of asthma in patients suffering from allergic rhinitis. Despite numerous clinical trials proving the importance of AIT in the treatment of allergic diseases, it still remains underused in clinical practice.
Ključne riječi
ALLERGEN IMMUNOTHERAPY; ASTHMA; CHILDREN
Hrčak ID:
300452
URI
Datum izdavanja:
17.4.2023.
Posjeta: 397 *